NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award

LAWRENCE, Mass., Sept. 1, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Chief Executive Officer, Jeffrey H. Burbank, is among the recipients of Mass High Tech, The Voice of New England Innovation, 2011 All-Stars Awards. The All-Stars Awards recognize 15 driven and influential leaders of New England's innovation economy.

(Logo:  http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The 2011 Mass High Tech All-Stars honorees represent a broad range of technology and service sectors, including robotics, software, economic development, ecommerce, entrepreneurship, medical devices and cleantech. They were selected from more than 100 nominees recommended by the technology community.

"These All-Stars have a proven record in leading not only their own companies but in helping their industry thrive," said Mass High Tech publisher Douglas Banks. "By combining this year's awards program with the BBJ's Rising Stars in Business, we are offering our All-Stars another opportunity for mentorship while giving the younger generation access to innovative role models."

From its inception, Jeffrey Burbank has led NxStage in pioneering home hemodialysis by providing life-changing therapy to dialysis patients. Under his leadership, NxStage succeeded in developing and commercializing the NxStage® System One™, the only truly portable home hemodialysis machine cleared by the Food and Drug Administration (FDA). The System One enables a more frequent therapy schedule, which clinical data shows is associated with positive outcomes relative to conventional in-center dialysis including improved survival, improved blood pressure management and other significant clinical and lifestyle benefits.

"I am honored to be recognized among this impressive list of New England innovators," said Burbank. "With over 5,000 patients and compelling clinical data in support of the improved clinical, quality of life and survival outcomes possible with more frequent hemodialysis using the System One, NxStage has accomplished much. As the leader in home hemodialysis, we look forward to the opportunities for growth and innovation ahead."

The Innovation All-Stars and Rising Stars will be profiled in a special report on MassHighTech.com, and will be recognized at an evening awards celebration and networking reception on Wednesday, Nov. 16 at the House of Blues in Boston. For more information about the event and to register, visit http://www.bizjournals.com/masshightech/event/51051.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.  When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Media Contacts:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
[email protected]
978-332-5923

MHT:
Douglas Banks
617 316 3272

SOURCE NxStage Medical, Inc.